S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
Log in

NASDAQ:FPRX - Five Prime Therapeutics Stock Price, Forecast & News

$4.32
-0.51 (-10.56 %)
(As of 02/27/2020 04:00 PM ET)
Today's Range
$4.27
Now: $4.32
$4.72
50-Day Range
$4.32
MA: $5.09
$6.04
52-Week Range
$3.18
Now: $4.32
$13.84
Volume604,731 shs
Average Volume477,977 shs
Market Capitalization$157.21 million
P/E RatioN/A
Dividend YieldN/A
Beta2.53
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FPRX
CUSIPN/A
Phone415-365-5600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$49.87 million
Book Value$7.48 per share

Profitability

Net Income$-140,450,000.00
Net Margins-921.30%

Miscellaneous

Employees209
Market Cap$157.21 million
Next Earnings Date2/27/2020 (Confirmed)
OptionableOptionable

Receive FPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for FPRX and its competitors with MarketBeat's FREE daily newsletter.


Five Prime Therapeutics (NASDAQ:FPRX) Frequently Asked Questions

What is Five Prime Therapeutics' stock symbol?

Five Prime Therapeutics trades on the NASDAQ under the ticker symbol "FPRX."

How were Five Prime Therapeutics' earnings last quarter?

Five Prime Therapeutics Inc (NASDAQ:FPRX) released its quarterly earnings data on Wednesday, November, 6th. The biotechnology company reported ($1.03) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.95) by $0.08. The biotechnology company had revenue of $2.98 million for the quarter, compared to analyst estimates of $4.33 million. Five Prime Therapeutics had a negative return on equity of 65.39% and a negative net margin of 921.30%. View Five Prime Therapeutics' Earnings History.

When is Five Prime Therapeutics' next earnings date?

Five Prime Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Five Prime Therapeutics.

What price target have analysts set for FPRX?

5 brokers have issued 1 year price objectives for Five Prime Therapeutics' shares. Their forecasts range from $5.00 to $24.00. On average, they anticipate Five Prime Therapeutics' share price to reach $12.25 in the next twelve months. This suggests a possible upside of 183.6% from the stock's current price. View Analyst Price Targets for Five Prime Therapeutics.

What is the consensus analysts' recommendation for Five Prime Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Five Prime Therapeutics in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Five Prime Therapeutics.

Has Five Prime Therapeutics been receiving favorable news coverage?

News coverage about FPRX stock has been trending extremely negative this week, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Five Prime Therapeutics earned a news impact score of -4.2 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View News Stories for Five Prime Therapeutics.

Are investors shorting Five Prime Therapeutics?

Five Prime Therapeutics saw a increase in short interest in the month of February. As of February 14th, there was short interest totalling 1,910,000 shares, an increase of 11.7% from the January 30th total of 1,710,000 shares. Based on an average trading volume of 472,100 shares, the short-interest ratio is currently 4.0 days. Approximately 5.4% of the shares of the stock are sold short. View Five Prime Therapeutics' Current Options Chain.

Who are some of Five Prime Therapeutics' key competitors?

What other stocks do shareholders of Five Prime Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Five Prime Therapeutics investors own include Nektar Therapeutics (NKTR), Novavax (NVAX), Ionis Pharmaceuticals (IONS), Opko Health (OPK), TG Therapeutics (TGTX), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), TherapeuticsMD (TXMD) and Amarin (AMRN).

Who are Five Prime Therapeutics' key executives?

Five Prime Therapeutics' management team includes the folowing people:
  • Mr. Aron Marc Knickerbocker, Pres, CEO & Director (Age 50)
  • Mr. Francis W. Sarena, Chief Strategy Officer & Sec. (Age 48)
  • Dr. Helen Louise Collins, Sr. VP & Chief Medical Officer (Age 56)
  • Dr. Peder K. Jensen, Advisor & Director (Age 64)
  • Mr. David V. Smith, Exec. VP & CFO

Who are Five Prime Therapeutics' major shareholders?

Five Prime Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BVF Inc. IL (21.39%), Renaissance Technologies LLC (4.84%), State Street Corp (1.72%), Man Group plc (1.50%), Geode Capital Management LLC (1.42%) and AQR Capital Management LLC (1.23%). Company insiders that own Five Prime Therapeutics stock include Andrew T Feldstein, Bvf Partners L P/Il, Franklin M Berger and Value Fund L P Biotechnology. View Institutional Ownership Trends for Five Prime Therapeutics.

Which institutional investors are selling Five Prime Therapeutics stock?

FPRX stock was sold by a variety of institutional investors in the last quarter, including Man Group plc, Assenagon Asset Management S.A., AXA, UBS Group AG, State Street Corp, Citigroup Inc., Bank of New York Mellon Corp and Algert Global LLC. View Insider Buying and Selling for Five Prime Therapeutics.

Which institutional investors are buying Five Prime Therapeutics stock?

FPRX stock was purchased by a variety of institutional investors in the last quarter, including BVF Inc. IL, Renaissance Technologies LLC, AQR Capital Management LLC, Jacobs Levy Equity Management Inc., Acadian Asset Management LLC, Russell Investments Group Ltd., Platinum Investment Management Ltd. and Geode Capital Management LLC. Company insiders that have bought Five Prime Therapeutics stock in the last two years include Andrew T Feldstein, Bvf Partners L P/Il and Value Fund L P Biotechnology. View Insider Buying and Selling for Five Prime Therapeutics.

How do I buy shares of Five Prime Therapeutics?

Shares of FPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Five Prime Therapeutics' stock price today?

One share of FPRX stock can currently be purchased for approximately $4.32.

How big of a company is Five Prime Therapeutics?

Five Prime Therapeutics has a market capitalization of $157.21 million and generates $49.87 million in revenue each year. The biotechnology company earns $-140,450,000.00 in net income (profit) each year or ($4.13) on an earnings per share basis. Five Prime Therapeutics employs 209 workers across the globe.View Additional Information About Five Prime Therapeutics.

What is Five Prime Therapeutics' official website?

The official website for Five Prime Therapeutics is http://www.fiveprime.com/.

How can I contact Five Prime Therapeutics?

Five Prime Therapeutics' mailing address is 111 Oyster Point Boulevard, South San Francisco CA, 94080. The biotechnology company can be reached via phone at 415-365-5600 or via email at [email protected]


MarketBeat Community Rating for Five Prime Therapeutics (NASDAQ FPRX)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  288 (Vote Outperform)
Underperform Votes:  235 (Vote Underperform)
Total Votes:  523
MarketBeat's community ratings are surveys of what our community members think about Five Prime Therapeutics and other stocks. Vote "Outperform" if you believe FPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FPRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel